Clinical Trial Update: EO2040 in Combination With Nivolumab, for Treatment of Patients With Minimal Residual Disease of Colorectal Cancer [Phase 2]

View source ↗

Summary

Phase 2 study of EO2040 in combination with nivolumab for colorectal cancer with minimal residual disease was terminated, and results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• EO2040 (EO2040)
• nivolumab (nivolumab)

Snippet

Sponsor: Enterome | Conditions: Colorectal Cancer | Phase 2 | Status: TERMINATED | Results posted: 2024-12-19